VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium

Dev Dyn. 2006 Dec;235(12):3413-22. doi: 10.1002/dvdy.20982.


To introduce temporal control in genetic experiments targeting the endothelium, we established a mouse line expressing tamoxifen-inducible Cre-recombinase (Cre-ERT2) under the regulation of the vascular endothelial cadherin promoter (VECad). Specificity and efficiency of Cre activity was documented by crossing VECad-Cre-ERT2 with the ROSA26R reporter mouse, in which a floxed-stop cassette has been placed upstream of the beta-galactosidase gene. We found that tamoxifen specifically induced widespread recombination in the endothelium of embryonic, neonatal, and adult tissues. Recombination was also documented in tumor-associated vascular beds and in postnatal angiogenesis assays. Furthermore, injection of tamoxifen in adult animals resulted in negligible excision (lower than 0.4%) in the hematopoietic lineage. The VECad-Cre-ERT2 mouse is likely to be a valuable tool to study the function of genes involved in vascular development, homeostasis, and in complex processes involving neoangiogenesis, such as tumor growth.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Antigens, CD / genetics*
  • Cadherins / genetics*
  • Endothelium, Vascular / embryology
  • Endothelium, Vascular / growth & development
  • Endothelium, Vascular / metabolism*
  • Female
  • Genes, Reporter
  • Integrases / genetics*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Models, Genetic
  • Pregnancy
  • Recombination, Genetic / drug effects
  • Tamoxifen / pharmacology


  • Antigens, CD
  • Cadherins
  • cadherin 5
  • Tamoxifen
  • Cre recombinase
  • Integrases